Cellectar BioSciences Inc. has presented its latest corporate presentation, highlighting the development of Phospholipid Drug Conjugates (PDCs). The company has validated its PDC platform, which shows promise in delivering various oncology therapeutic modalities, including radioisotopes. Notably, their advanced Phospholipid Radioconjugate (PRC), iopofosine I-131, has exceeded efficacy endpoints in a phase 2 study for Waldenstrom's macroglobulinemia $(WM)$. The company has finalized its confirmatory study design and regulatory pathway for potential FDA accelerated approval. Additionally, Cellectar has ongoing studies for other assets, such as CLR 125 and CLR 225, targeting triple-negative breast cancer and pancreatic cancer, respectively. You can access the full presentation through the link below.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。